HIGHLIGHTS
- who: Judith M. Vlaar from the Center for MolecularUniversity Medical have published the research: Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer, in the Journal: Scientific Reports Scientific Reports
- what: The authors demonstrate that the recurrent alterations lead to constitutively activated AHR signaling and induce an oncogenic phenotype in bladder cells. The authors show high prevalence of AHR alterations in urinary tract cancers and provide functional validations to support that these aberrations are oncogenic and drive urinary tract cancer. The authors demonstrate that the hAHRQ383H mutation leads to increased . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.